| 摘要 |
<p>Disclosed is a method for therapy selection for a subject with a malignant cancer involving aberrant c-Met signaling, the method comprising: (a) detecting and/or quantifying the expression level and/or activation level of cMet protein in a sample taken from the subject; (b) detecting and/or quantifying the expression level and/or activation level of HER3 protein in the sample; (c) comparing the expression level and/or activation level of cMet protein and/or HER3 protein in the sample to (i) the expression level and/or activation level of a control protein and/or (ii) the expression level and/or activation level of cMet protein and/or HER3 protein in a control sample; and (d) determining whether to administer a cMet inhibitor alone or a cMet inhibitor in combination with a pathway-directed therapy based upon a difference between the expression level and/or activation level of cMet protein and/or HER3 protein in the sample compared to the control protein and/or control sample, wherein the cMet inhibitor should be administered alone when the expression level and/or activation level of cMet protein and/or HER3 protein in the sample is determined to range from medium to high compared to the control protein and/or control sample.</p> |
